Jing Zhu

机构：Tongji University, Chongqing University, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, Shanghai Tenth People's Hospital · ORCID：0000-0002-4784-3908

发表论文 44 篇 · 总被引 388 次 · h-index 11

代表论文

• Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors (2020 · Lung Cancer · 被引 33)
• Significance of PIVKA‑II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus‑associated hepatocellular carcinoma (2018 · Oncology Letters · 被引 24)
• miR‑142‑5p inhibits pancreatic cancer cell migration and invasion by targeting PIK3CA (2020 · Molecular Medicine Reports · 被引 23)
• Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective (2021 · Pharmaceutics · 被引 17)
• Identification of KW-2449 as a dual inhibitor of ferroptosis and necroptosis reveals that autophagy is a targetable pathway for necroptosis inhibitors to prevent ferroptosis (2024 · Cell Death and Disease · 被引 16)
• A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China (2022 · Targeted Oncology · 被引 11)